Wire flash
FinanceVertex to acquire Crinetics for $10 bln; CRNX shares surge 99%
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
Crinetics Pharmaceuticals (CRNX) stock surged 99% this week after Vertex Pharmaceuticals (VRTX) agreed to acquire it for $85 per share in an all-cash deal valued at approximately $10 billion. The acquisition, expected to close in Q3 2026, gives Vertex access to Crinetics' endocrine franchise, including PALSONIFY (paltusotine), a recently approved once-daily oral treatment for acromegaly, and atumelnant, a Phase 3 candidate for congenital adrenal hyperplasia and Cushing's syndrome. Vertex projects the acquired assets could generate over $5 billion in peak annual sales and contribute earnings accretion by 2029. The deal also triggered a re-rating of endocrine rare-disease peers, with Neurocrine Biosciences (NBIX) gaining 6.24%, Corcept Therapeutics (CORT) rising 5.04%, and Ascendis Pharma (ASND) up 3.51%, as investors view them as potential M&A targets. CRNX shares now trade just under the $85 offer price, limiting upside unless a competing bid emerges.
Source report
Danielle Liverance Thu, July 9, 2026 at 10:29 AM PDT 3 min read
Quick Read
- Vertex's $85-per-share all-cash acquisition sent CRNX up 116% on a franchise the company projects will exceed $5 billion in peak annual sales.
- NBIX gained 6% and CORT rose 5% as investors repriced endocrine rare-disease specialists as potential M&A targets following the deal.
- Trading just under the $85 cash offer, CRNX upside is capped unless a competing bid emerges before the expected Q3 2026 close.
Crinetics Pharmaceuticals (NASDAQ: CRNX) shares have climbed 99% this week, from $42.03 at Monday's close to $83.54 earlier today. The simple reason: Vertex Pharmaceuticals (NASDAQ: VRTX) agreed to acquire it.
Vertex's $10 Billion All-Cash Bid Fuels the Surge
The catalyst arrived after the market close on July 6: Vertex agreed to buy Crinetics for approximately $10 billion, or $85.00 per share in all cash. The transaction was unanimously approved by both boards and is expected to close in Q3 2026. Vertex plans to finance the deal with cash and debt.
The prize is Crinetics' endocrine franchise:
- PALSONIFY (paltusotine) — the first once-daily oral somatostatin receptor type 2 nonpeptide agonist for acromegaly. It cleared the FDA in September 2025 and won European Commission approval in April 2026. Q1 2026 product sales hit $10.31 million, with 263 unique prescribers and roughly 70% of patients on reimbursed therapy.
- Atumelnant — a Phase 3 candidate for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome.
Vertex projects the acquired assets could deliver over $5 billion in peak annual sales and contribute earnings accretion by 2029.
Endocrine Peers Get a Re-Rating
Vertex is stepping outside cystic fibrosis and building a fifth business group in endocrine diseases. This validation puts a fresh spotlight on the small cluster of rare-disease specialists in the same neighborhood. Vertex shares themselves barely moved on the week, gaining 0.08% to $498.43, reflecting investor caution about the price tag.
The most direct competitive read-throughs are into Cushing's syndrome and CAH:
| Company | Ticker | Weekly Gain | Relevant Program | |---------|--------|-------------|------------------| | Neurocrine Biosciences | NASDAQ: NBIX | +6.24% | CRENESSITY (crinecerfont) for classic CAH — $153.30M in Q1 2026 revenue | | Corcept Therapeutics | NASDAQ: CORT | +5.04% | Relacorilant for Cushing's syndrome; newly approved ovarian cancer indication Lifyorli | | Ascendis Pharma | NASDAQ: ASND | +3.51% | Adjacent endocrine rare-disease peer with YORVIPATH and YUVIWEL |
Those moves arrive against a backdrop where a scaled acquirer just paid roughly $85 per share for a company whose analyst target sat at $83.73 and whose full-year 2026 revenue is pegged around $69 million. Investors sifting for the next endocrine tuck-in are exactly the audience that reads through to names like these — one reason breakout-driven M&A watchlists get updated after weeks like this one.
What to Watch
With CRNX at $83.54 and the cash offer at $85.00, upside is limited unless a competing bid emerges before the expected Q3 2026 close.
24/7 Wall St.
Source
Yahoo FinanceWestern
Part of this Story
Vertex acquires Crinetics for $10B to expand into rare endocrine diseases